Complementary activation of peripheral natural killer cell immunity in nasopharyngeal carcinoma

NK cells and αβ‐ and γδ‐CTL play important roles in cellular immunity against tumors. We previously demonstrated that NPC patients have a quantitative and qualitative deficit in γδ‐CTL and EBV‐specific αβ‐CTL when compared to normal subjects and NPC long‐term survivors. In this study we report further observations of a complementary activation of peripheral NK cells in NPC patients. The NK cells in these patients, compared to those of healthy subjects and NPC survivors, were preferentially activated in response to the stimulation of myeloma cell line XG‐7 and expanded in the presence of exogenous IL‐2. The production of IFN‐γ was lowest in the patient group, whereas IL‐12, IL‐15 and TNF‐α were produced in higher levels in patients than in the donors and survivors. The cytolytic effect of the NK cells against NPC cells in the patient group was also higher than that of the donors and survivors. Furthermore, the patients at later stages of NPC had lower γδ‐CTL activity but higher NK cytotoxicity towards NPC targets, with higher production of IL‐12, IL‐15 and TNF‐α but lower production of IFN‐γ than in patients at earlier stages. This might be part of a triggered compensatory re‐activation of the innate immunity, believed to be mediated through various cytokines and chemokines when adaptive T cell immunity is breached. Together, these data suggest complementary roles of innate and adaptive immune response in tumor immunity where NK cells, γδ‐ and αβ‐CTL compensate for the deficits of one another at different stages of tumor invasion. (Cancer Sci 2006; 97: 912–919)

[1]  T. H. Bø,et al.  CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles , 2005, Cytometry. Part B, Clinical cytometry.

[2]  R. Foà,et al.  Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. , 2005, Haematologica.

[3]  H. Ikeda,et al.  The critical role of type‐1 innate and acquired immunity in tumor immunotherapy , 2004, Cancer science.

[4]  L. Malmgaard Induction and regulation of IFNs during viral infections. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[5]  I. McInnes,et al.  Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. , 2004, Current opinion in pharmacology.

[6]  O. Hrusak,et al.  Antigen expression patterns reflecting genotype of acute leukemias , 2002, Leukemia.

[7]  J. Sham,et al.  Peripheral γδ T‐cell deficit in nasopharyngeal carcinoma , 2002 .

[8]  F. Shi,et al.  The Natural Killer Cell – Friend or Foe in Autoimmune Disease? , 2002, Scandinavian journal of immunology.

[9]  I. McInnes,et al.  The role of innate mediators in inflammatory response. , 2002, Molecular immunology.

[10]  M. Collins,et al.  IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. , 2002, Immunity.

[11]  N. Day,et al.  Innate immunity and its role against infections. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  Eric O Long Tumor cell recognition by natural killer cells. , 2002, Seminars in cancer biology.

[13]  A. Luster The role of chemokines in linking innate and adaptive immunity. , 2002, Current opinion in immunology.

[14]  C. Biron,et al.  Innate immune responses to LCMV infections: natural killer cells and cytokines. , 2002, Current topics in microbiology and immunology.

[15]  D. Pardoll Stress, NK Receptors, and Immune Surveillance , 2001, Science.

[16]  K. Yuen,et al.  Adoptive transfer of autologous Epstein‐Barr virus–specific cytotoxic T cells for nasopharyngeal carcinoma , 2001, International journal of cancer.

[17]  Julia M. Lewis,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[18]  C. Feighery,et al.  Selective Expansion and Partial Activation of Human NK Cells and NK Receptor-Positive T Cells by IL-2 and IL-151 , 2001, The Journal of Immunology.

[19]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[20]  Ciriana Orabona,et al.  Positive Regulatory Role of IL-12 in Macrophages and Modulation by IFN-γ1 , 2001, The Journal of Immunology.

[21]  Brubaker Jo,et al.  Role of interleukin-13 in innate and adaptive immunity. , 2001 .

[22]  H. Tilg,et al.  Interferon-alpha in inflammation and immunity. , 2001, Cellular and molecular biology.

[23]  Jonathan W. Heusel,et al.  Vital Involvement of a Natural Killer Cell Activation Receptor in Resistance to Viral Infection , 2001, Science.

[24]  K. Chan,et al.  Anti‐tumor effects of human peripheral γδ T cells in a mouse tumor model , 2001 .

[25]  Pei-Hua Lu,et al.  CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells , 2001, Cancer Immunology, Immunotherapy.

[26]  C. Wong,et al.  Distinct Tumour Specificity and IL‐7 Requirements of CD56−and CD56+ Subsets of Human γδ T Cells , 2001 .

[27]  T. Kishida,et al.  Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer , 2001, Cancer Immunology, Immunotherapy.

[28]  L. Lanier,et al.  Immune inhibitory receptors. , 2000, Science.

[29]  O. Tsitsilonis,et al.  Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice , 2000, European journal of immunology.

[30]  Y. Kanda,et al.  The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia , 2000, Cancer.

[31]  D. Kabelitz,et al.  Antigen Recognition by Human γδ T Lymphocytes , 2000, International Archives of Allergy and Immunology.

[32]  A. Ramsay,et al.  Cytokines in innate and adaptive immunity. , 2000, Reviews in immunogenetics.

[33]  C. Biron,et al.  Natural killer cells in antiviral defense: function and regulation by innate cytokines. , 1999, Annual review of immunology.

[34]  K. Hellström,et al.  T cell immunity to tumor antigens. , 1998, Critical reviews in immunology.

[35]  P Parham,et al.  Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. , 1997, Immunity.

[36]  L. Axelsson,et al.  CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. , 1997, Blood.

[37]  E. Podack,et al.  Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. , 1996, Journal of immunology.

[38]  M. Ferrarini,et al.  Daudi lymphoma killing triggers the programmed death of cytotoxic V gamma 9/V delta 2 T lymphocytes. , 1995, Journal of immunology.

[39]  R. Martin,et al.  CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. , 1994, Journal of immunological methods.

[40]  M. Jourdan,et al.  Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.

[41]  X M Wang,et al.  A new microcellular cytotoxicity test based on calcein AM release. , 1993, Human immunology.

[42]  A. Komiyama,et al.  Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection. , 1987, Clinical and experimental immunology.

[43]  J. Ho Stage classification of nasopharyngeal carcinoma: a review. , 1978, IARC scientific publications.